These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 35166870)

  • 21. Radiation techniques for esophageal cancer.
    Zhang M; Wu AJ
    Chin Clin Oncol; 2017 Oct; 6(5):45. PubMed ID: 29129085
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of the effects of radiotherapy doses of 50.4 Gy and 60 Gy on outcomes of chemoradiotherapy for thoracic esophageal cancer: subgroup analysis based on the Comprehensive Registry of Esophageal Cancer in Japan from 2009 to 2011 by the Japan Esophageal Society.
    Nemoto K; Kawashiro S; Toh Y; Numasaki H; Tachimori Y; Uno T; Jingu K; Matsubara H
    Esophagus; 2020 Apr; 17(2):122-126. PubMed ID: 31912332
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Radiation Therapy for Locally Advanced Esophageal Cancer.
    Chun SG; Skinner HD; Minsky BD
    Surg Oncol Clin N Am; 2017 Apr; 26(2):257-276. PubMed ID: 28279468
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Influence of radiation dose and predicted tumor invasion depth on local recurrence after definitive chemoradiotherapy for stage 0-I esophageal squamous cell carcinoma: a propensity score-weighted, retrospective, observational study.
    Ikawa T; Ishihara R; Matsueda K; Konishi K; Yamamoto S; Morimoto M; Kanayama N; Teshima T
    BMC Cancer; 2022 Mar; 22(1):301. PubMed ID: 35313853
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The association of primary tumor site with acute adverse event and efficacy of definitive chemoradiotherapy for cStage II/III esophageal cancer: an exploratory analysis of JCOG0909.
    Hironaka S; Komori A; Machida R; Ito Y; Takeuchi H; Ogawa G; Kato K; Onozawa M; Minashi K; Yano T; Nakamura K; Tsushima T; Hara H; Nozaki I; Ura T; Chin K; Fukuda H; Kitagawa Y
    Esophagus; 2020 Oct; 17(4):417-424. PubMed ID: 32342253
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Radiochemotherapy for esophageal cancer: which nodes should be irradiated?].
    Créhange G; Quivrin M; Vulquin N; Serre AA; Maingon P
    Cancer Radiother; 2014 Oct; 18(5-6):577-82. PubMed ID: 25201634
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Salvage surgery in esophageal cancer : Feasibility in patients after definitive radiochemotherapy (> 50 Gy)].
    Schmidt T; Sisic L; Sterzing F; Haag GM; Kunzmann R; Grenacher L; Weichert W; Jäger D; Büchler MW; Ott K
    Chirurg; 2015 Oct; 86(10):955-62. PubMed ID: 25715974
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High-dose definitive concomitant chemoradiotherapy in non-metastatic locally advanced esophageal cancer: toxicity and outcome.
    Hurmuzlu M; Monge OR; Smaaland R; Viste A
    Dis Esophagus; 2010 Apr; 23(3):244-52. PubMed ID: 19664075
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical outcomes and prognostic factors of definitive radiotherapy for esophageal cancer.
    Tonoiso C; Ikushima H; Kubo A; Kawanaka T; Funatani S; Kudo T; Yoshida T; Miyamoto H; Harada M; Takayama T; Tangoku A
    J Med Invest; 2019; 66(1.2):99-105. PubMed ID: 31064964
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intensity-modulated versus 3-dimensional conformal radiotherapy in the definitive treatment of esophageal cancer: comparison of outcomes and acute toxicity.
    Haefner MF; Lang K; Verma V; Koerber SA; Uhlmann L; Debus J; Sterzing F
    Radiat Oncol; 2017 Aug; 12(1):131. PubMed ID: 28810885
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dose-response relationship in locoregional control for patients with stage II-III esophageal cancer treated with concurrent chemotherapy and radiotherapy.
    Zhang Z; Liao Z; Jin J; Ajani J; Chang JY; Jeter M; Guerrero T; Stevens CW; Swisher S; Ho L; Yao J; Allen P; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):656-64. PubMed ID: 15708243
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase I/II radiation dose escalation trial using simultaneous integrated boost technique with elective nodal irradiation and concurrent chemotherapy for unresectable esophageal Cancer.
    Li C; Ni W; Wang X; Zhou Z; Deng W; Chang X; Chen D; Feng Q; Liang J; Wang X; Deng L; Wang W; Bi N; Zhang T; Xiao Z
    Radiat Oncol; 2019 Mar; 14(1):48. PubMed ID: 30876442
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Phase II clinical trial of concurrent chemoradiotherapy (cisplatin plus 5-fluorouracil) for esophageal cancer].
    Lin Q; Gao XS; Qiao XY; Chen K; Wang YD; Zhou ZG
    Ai Zheng; 2008 Oct; 27(10):1077-81. PubMed ID: 18851788
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is Concurrent Chemotherapy With Radiotherapy for Esophageal Cancer Beneficial in Patients Aged 80 Years or Older?
    Jingu K; Takahashi N; Murakami Y; Ishikawa K; Itasaka S; Takahashi T; Isohashi F; Sakayauchi T; Ogawa K;
    Anticancer Res; 2019 Aug; 39(8):4279-4283. PubMed ID: 31366518
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term results of radiochemotherapy for solitary lymph node metastasis after curative resection of esophageal cancer.
    Jingu K; Ariga H; Nemoto K; Narazaki K; Umezawa R; Takeda K; Koto M; Sugawara T; Kubozono M; Miyata G; Onodera K; Yamada S
    Int J Radiat Oncol Biol Phys; 2012 May; 83(1):172-7. PubMed ID: 22079727
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Survival after definitive (chemo)radiotherapy in esophageal cancer patients: a population-based study in the north-East Netherlands.
    Smit JK; Muijs CT; Burgerhof JG; Paardekooper G; Timmer PR; Muller K; Woutersen D; Mul VE; Beukema JC; Hospers GA; van Dijk BA; Langendijk JA; Plukker JT
    Ann Surg Oncol; 2013 Jun; 20(6):1985-92. PubMed ID: 23274534
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Radiotherapy and chemotherapy in locally advanced non-small cell lung cancer: preclinical and early clinical data.
    Reboul FL
    Hematol Oncol Clin North Am; 2004 Feb; 18(1):41-53. PubMed ID: 15005280
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association between radiation dose and pathological complete response after preoperative radiochemotherapy in esophageal squamous cell cancer.
    Ordu AD; Nieder C; Geinitz H; Scherer V; Kup PG; Schuster T; Combs SE; Fakhrian K
    Anticancer Res; 2014 Dec; 34(12):7255-61. PubMed ID: 25503157
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of paclitaxel in combination with cisplatin (TP), carboplatin (TC) or fluorouracil (TF) concurrent with radiotherapy for patients with local advanced oesophageal squamous cell carcinoma: a three-arm phase III randomized trial (ESO-Shanghai 2).
    Ai D; Chen Y; Liu Q; Zhang J; Deng J; Zhu H; Ren W; Zheng X; Li Y; Wei S; Ye J; Zhou J; Lin Q; Luo H; Cao J; Li J; Huang G; Wu K; Fan M; Yang H; Zhu Z; Zhao W; Li L; Fan J; Badakhshi H; Zhao K
    BMJ Open; 2018 Oct; 8(10):e020785. PubMed ID: 30344165
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neoadjuvant chemoradiation followed by surgery versus surgery alone for patients with adenocarcinoma or squamous cell carcinoma of the esophagus (CROSS).
    van Heijl M; van Lanschot JJ; Koppert LB; van Berge Henegouwen MI; Muller K; Steyerberg EW; van Dekken H; Wijnhoven BP; Tilanus HW; Richel DJ; Busch OR; Bartelsman JF; Koning CC; Offerhaus GJ; van der Gaast A
    BMC Surg; 2008 Nov; 8():21. PubMed ID: 19036143
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.